TOPICAL AVASTIN MAY DECREASE PKP GRAFT REJECTION

Eur J Ophthalmol 2009; 19: 870 - 872

Short-term topical bevacizumab (Avastin) therapy may potentially offer a safer and more effective alternative in treating graft rejection after penetrating keratoplasty (corneal transplant).

Comments

Popular posts from this blog

IMPLANTABLE COLLAMER LENS APPEARS BETTER THAN LASIK OR PRK FOR MODERATE TO HIGH MYOPIC PATIENTS

RINSING YOUR CONTACT LENS CASE IS NOT ENOUGH